Álvaro Avezum

92.3k citations

188 papers · 22.6k indexed · 8 hit papers · h-index 55

Cardiology and Cardiovascular Medicine top 0.05%
Surgery top 0.2%
Public Health, Environmental and Occupational Health top 0.2%
Epidemiology top 0.5%
Endocrinology, Diabetes and Metabolism top 0.2%

Co-authors: Salim Yusuf Andrzej Budaj Fernando Laņas George Varigos Prem Pais Lisheng Liu Stephanie Ôunpuu Steven Hawken
Topics: Acute Myocardial Infarction Research (52 papers)Atrial Fibrillation Management and Outcomes (35 papers)Antiplatelet Therapy and Cardiovascular Diseases (23 papers)
Cited by: Cardiology and Cardiovascular Medicine Internal Medicine Endocrinology, Diabetes and Metabolism
Journals: New England Journal of Medicine The Lancet JAMA
Partner nations: Brazil United States Canada

In The Last Decade

Álvaro Avezum

175 papers receiving 21.5k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study

2004 8.2k citations Salim Yusuf, Álvaro Avezum et al. profile →
Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial

2011 1.4k citations Salim Yusuf, Denis Xavier et al. profile →
A Validated Prediction Model for All Forms of Acute Coronary Syndrome

2004 1.2k citations Álvaro Avezum et al. profile →
Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE)

2006 1.1k citations Álvaro Avezum et al. profile →
Randomized Trial of Benznidazole for Chronic Chagas’ Cardiomyopathy

2015 719 citations José Antônio Marin‐Neto, Álvaro Avezum et al. profile →
Comparison of Candesartan, Enalapril, and Their Combination in Congestive Heart Failure

1999 662 citations Robert S. McKelvie, Salim Yusuf et al. Circulation profile →
Early versus Delayed Invasive Intervention in Acute Coronary Syndromes

2009 582 citations Álvaro Avezum, Jun Zhu et al. profile →
Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin

2012 399 citations Jeff S. Healey, John W. Eikelboom et al. Circulation profile →

Peers

Countries citing papers authored by Álvaro Avezum

Since Specialization

Citations

This map shows the geographic impact of Álvaro Avezum's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Álvaro Avezum with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Álvaro Avezum more than expected).

Fields of papers citing papers by Álvaro Avezum

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Álvaro Avezum. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Álvaro Avezum. The network helps show where Álvaro Avezum may publish in the future.

Co-authorship network of co-authors of Álvaro Avezum

This figure shows the co-authorship network connecting the top 25 collaborators of Álvaro Avezum. A scholar is included among the top collaborators of Álvaro Avezum based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Álvaro Avezum. Álvaro Avezum is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Mapping the Dynamic Complexity of Hypertension Management in São Paulo, Brazil 2026 ·International Journal of Public Health ·(unknown),(unknown),(unknown),(unknown),Álvaro Avezum,Luciano F. Drager,Luiz Aparecido Bortolotto,(unknown),Daniel Cobos Muñoz	0
2	Clinical significance of a new diagnosis of atrial fibrillation in patients with vascular disease 2025 ·Heart Rhythm ·Alexander P. Benz,Marco Alings,Jackie Bosch,Álvaro Avezum,Deepak L. Bhatt,Jeff S. Healey,Linda Johnson,William F. McIntyre,Petr Widimský,Qilong Yi,Salim Yusuf,Stuart J. Connolly,John W. Eikelboom	1
3	Incidence and Predictors of Clinical Outcomes in Patients with Valvular and Nonvalvular Atrial Fibrillation Using Vitamin K Antagonists 2025 ·Arquivos Brasileiros de Cardiologia ·(unknown),Gustavo Bernardes de Figueiredo Oliveira,(unknown),(unknown),(unknown),(unknown),Gregory Y H Lip,Álvaro Avezum	0
4	An Intersectoral Approach to Hypertension Care: Solutions for Improving Blood Pressure Control in São Paulo, Brazil 2024 ·American Journal of Hypertension ·Álvaro Avezum,Luciano F. Drager,(unknown),(unknown),(unknown),(unknown),Luiz Aparecido Bortolotto,Marta S. Palmeirim,(unknown),(unknown),(unknown),(unknown),Daniel Cobos Muñoz,(unknown),(unknown),(unknown),Caitlin Jarrett,(unknown)	2
5	Impact of Frailty on the Benefits of Dual Pathway Inhibition for the Secondary Prevention of Cardiovascular Events in the COMPASS Randomised Trial 2024 ·Canadian Journal of Cardiology ·Darryl P. Leong,Jackie Bosch,Deepak L. Bhatt,Álvaro Avezum,Fei Yuan,Salim Yusuf,John W. Eikelboom	3
6	Alcohol Intake as a Risk Factor for Acute Stroke 2022 ·Neurology ·Andrew Smyth,Martin O’Donnell,Sumathy Rangarajan,Graeme J. Hankey,Shahram Oveisgharan,Michelle Canavan,(unknown),Denis Xavier,Hongye Zhang,Albertino Damasceno,Álvaro Avezum,Nana Pogosova,Aytekin Oğuz,Danuta Ryglewicz,Helle K. Iversen,Fernando Laņas,Annika Rosengren,Salim Yusuf,Peter Langhorne,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown)	31
7	Anger or emotional upset and heavy physical exertion as triggers of stroke: the INTERSTROKE study 2021 ·European Heart Journal ·Andrew Smyth,Martin O’Donnell,Graeme J. Hankey,Sumathy Rangarajan,Patricio López‐Jaramillo,Denis Xavier,Hongye Zhang,Michelle Canavan,Albertino Damasceno,Peter Langhorne,Álvaro Avezum,Nana Pogosova,Aytekin Oğuz,Salim Yusuf,(unknown)	15
8	Antihypertensives and Statin Therapy for Primary Stroke Prevention: A Secondary Analysis of the HOPE-3 Trial 2021 ·Stroke ·Jackie Bosch,Eva Lonn,Gilles R. Dagenais,Peggy Gao,Patricio López‐Jaramillo,Jun Zhu,Prem Pais,Álvaro Avezum,Karen Sliwa,И Е Чазова,Ron J.G. Peters,Claes Held,Khalid Yusoff,Basil S. Lewis,William D. Toff,Kamlesh Khunti,Christopher M. Reid,Lawrence A. Leiter,Salim Yusuf,Robert G. Hart,(unknown)	15
9	Síndrome do desconforto respiratório agudo associada à COVID-19 tratada com DEXametasona (CoDEX): delineamento e justificativa de um estudo randomizado 2020 ·LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) ·Bruno Martins Tomazini,Israel Silva Maia,Flávia Regina Bueno,(unknown),(unknown),Eduardo Leite Vieira Costa,(unknown),(unknown),(unknown),Alexandre Biasi Cavalcanti,Régis Goulart Rosa,Álvaro Avezum,Viviane Cordeiro Veiga,Renato D. Lópes,Lucas Petri Damiani,Flávia Ribeiro Machado,Otávio Berwanger,Luciano César Pontes Azevedo	5
10	Os Percentis e Pontos de Corte da Circunferência Abdominal para Obesidade em uma Ampla Amostra de Estudantes de 6 a 10 Anos de Idade do Estado de São Paulo, Brasil 2020 ·Arquivos Brasileiros de Cardiologia ·(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),Luı́z Antonio Machado César,Ibraim Pinto,(unknown),(unknown),Cleber Camacho,Álvaro Avezum,Carine Teles Sangaleti,Fernanda Marciano Consolim‐Colombo	5
11	Apixaban in Comparison With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease 2015 ·Circulation ·Álvaro Avezum,Renato D. Lópes,Phillip J. Schulte,Fernando Laņas,Bernard J. Gersh,Michael Hanna,Prem Pais,Çetin Erol,Rafael Díaz,M. Cecilia Bahit,Jozef Bartunek,Raffaele De Caterina,Shinya Goto,Witold Rużyłło,Jun Zhu,Christopher B. Granger,John H. Alexander	166
12	Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarinbreakdown → 2012 ·Circulation ·Jeff S. Healey,John W. Eikelboom,James D. Douketis,Lars Wallentin,Jonas Oldgren,Sean Yang,Ellison Themeles,Hein Heidbüchel,Álvaro Avezum,Paul Reilly,Stuart J. Connolly,Salim Yusuf,Michael D. Ezekowitz	399
13	Relationship Between Healthy Diet and Risk of Cardiovascular Disease Among Patients on Drug Therapies for Secondary Prevention 2012 ·Circulation ·Mahshid Dehghan,Andrew Mente,Koon Teo,Peggy Gao,Peter Sleight,Gilles R. Dagenais,Álvaro Avezum,Jeffrey L. Probstfield,(unknown),Salim Yusuf	122
14	Abstract 15937: Comparison of Dabigatran versus Warfarin in Diabetic Patients with Atrial Fibrillation: Results from the RE-LY Trial 2012 ·Circulation ·Harald Darius,Andreas Clemens,Jeff S. Healey,Álvaro Avezum,Rangadham Nagarakanti,Ashley Chin,Herbert Noack,Stuart J. Connolly	4
15	Population awareness on cardiovascular risk factors: a developing country experience PrevenAção 2008 ·Circulation ·Álvaro Avezum,(unknown),(unknown),(unknown),José Antônio Marin‐Neto,MC Bertolami,Clara Llorens,(unknown),Andrea Di Marco,Flávio Fonseca Nobre	1
16	V Diretrizes Brasileiras de Hipertensão Arterial 2007 ·Arquivos Brasileiros de Cardiologia ·(unknown),Marco Machado,(unknown),Andréa Tayse de Lima Gomes,(unknown),(unknown),(unknown),(unknown),Alberto Silva,Marcelo Chiara Bertolami,(unknown),Carlos Eduardo Jordão Machado,C. L. M. Forjaz,(unknown),Álvaro Avezum,E M Krieger,Lucélia Batista Neves Cunha Magalhães,(unknown),Mario Maranhão,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown)	252
17	Estudos de farmacoeconomia e análises econômicas: conceitos básicos 2007 ·Hélio Penna Guimarães,(unknown),Lígia Nasi Laranjeira,Álvaro Avezum	4
18	Os dez mandamentos do ensaio clínico randomizado - princípios para avaliação crítica da literatura médica 2006 ·Otávio Berwanger,Hélio Penna Guimarães,Álvaro Avezum,Leopoldo Soares Piegas	2
19	Epidemiologia do infarto agudo do miocárdio 2006 ·Hélio Penna Guimarães,Álvaro Avezum,Leopoldo Soares Piegas	4
20	Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy: The randomized evaluation of strategies for left ventricular dysfunction pilot study 2000 ·Circulation ·Michel White,Salim Yusuf,Robert S. McKelvie,(unknown),James B. Young,Roberto Latini,Janice Pogue,Robert J. Burns,Jeffrey L. Probstfield,Ross T. Tsuyuki,Aldo P. Maggioni,Álvaro Avezum,Jean-Lucien Rouleau	146

About Álvaro Avezum

Álvaro Avezum is a scholar working on Cardiology and Cardiovascular Medicine, Internal Medicine and Family Practice, having authored 188 papers that have together received 22.6k indexed citations. Recurring topics across this work include Acute Myocardial Infarction Research (52 papers), Atrial Fibrillation Management and Outcomes (35 papers) and Antiplatelet Therapy and Cardiovascular Diseases (23 papers). The work is most often cited by research in Cardiology and Cardiovascular Medicine (13.8k citations), Internal Medicine (1.6k citations) and Endocrinology, Diabetes and Metabolism (3.0k citations). Álvaro Avezum has collaborated with scholars based in Brazil, United States and Canada. Frequent co-authors include Salim Yusuf, Andrzej Budaj, Fernando Laņas, George Varigos, Prem Pais, Lisheng Liu, Stephanie Ôunpuu, Steven Hawken, Matthew McQueen and Kim A. Eagle. Their work appears in journals such as New England Journal of Medicine, The Lancet and JAMA.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact